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Abstract
In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell 
transplantation (auto-HCT), peripheral blood progenitor cells (PBPCs) may be collected following 
mobilization with growth factor alone (GF) or cytotoxic chemotherapy plus GF ( (CC+GF). It is 
uncertain whether the method of mobilization affects post-transplant outcomes. We compared 
these mobilization strategies in a retrospective analysis of 968 patients with MM from the Center 
for International Blood and Marrow Transplant Research database who received an auto-HCT in 
the US and Canada between 2007 and 2012. The kinetics of neutrophil engraftment (≥ 0.5 × 
109/L) was similar between groups (13 vs. 13 days, P=0.69) while platelet engraftment (≥ 20 × 
109/L) was slightly faster with CC+GF (19 vs. 18 days, P=0.006). Adjusted 3-years PFS was 43% 
(95% C.I. 38–48) in GF and 40% (95% C.I. 35–45) in CC+GF, P=0.33. Adjusted 3-years OS was 
82% (95% C.I. 78–86) vs. 80% (95% C.I. 75–84), P=0.43 and adjusted 5-year OS was 62% 
(95C.I. 54–68) vs. 60% (95% C.I. 52–67), P=0.76, for GF and CC+GF respectively. We conclude 
that MM patients undergoing auto-HCT have similar outcomes irrespective of the method of 
mobilization and found no evidence that the addition of chemotherapy to mobilization contributes 
to disease control.
INTRODUCTION
Multiple myeloma is currently the most common indication for autologous hematopoietic 
cell transplantation (auto-HCT) based on the prolongation of event-free and overall survival 
(OS) when compared to conventional chemotherapy alone.1–4 Currently 99% of auto-HCTs 
in adults utilize peripheral blood progenitor cells (PBPCs) as the graft source. PBPCs for 
transplantation may be mobilized either by hematopoietic growth factors (G-CSF and GM-
CSF) alone (GF) or cytotoxic chemotherapy plus growth factor (CC+GF). However, the 
optimal method for mobilization of hematopoietic progenitor cells is unknown.
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Proponents of CC+GF mobilization argue that the anti-myeloma activity of the 
chemotherapy agent contributes to long term disease control. In addition, CC+GF 
mobilization is associated with higher CD34+ yields than GF mobilization.5 Because 
induction therapy with lenalidomide has known detrimental effects on CD34+ yield,6–9 CC
+GF mobilization has been proposed as preferred mobilization strategy for these patients 
due to the higher incidence of mobilization failure with GF.10, 11
The impact of chemotherapy in the mobilization regimen to disease control is 
controversial.12 Furthermore, CC+GF mobilization can be associated with significant 
morbidity with increased risks of infection and hospitalization, and increased costs.5, 12–16 
In this study, we analyzed the CIBMTR database to compare the outcome of patients with 
MM receiving autologous HCT using PBSCs obtained by CC+GF mobilization versus GF 
mobilization.
METHODS
Data source
The CIBMTR® is a research collaboration between the National Marrow Donor Program® 
(NMDP)/Be The Match® and the Medical College of Wisconsin.. Established in 2004, it 
receives data from > 320 transplantation centers worldwide on allogeneic and autologous 
HCT. Data are submitted to the Statistical Center at the Medical College of Wisconsin in 
Milwaukee and the NMDP Coordinating Center in Minneapolis, where computerized checks 
for discrepancies, physicians' review of submitted data, and on-site audits of participating 
centers ensure data quality. Observational studies conducted by the CIBMTR are performed 
with approval of the institutional review boards of the National Marrow Donor Program and 
the Medical College of Wisconsin.
Study design
The primary objective of the study was to compare the progression-free survival (PFS) of 
patients receiving an auto-HCT after GF versus CC+GF mobilization for symptomatic MM. 
Secondary endpoints included OS, non-relapse mortality (NRM), and engraftment kinetics.
The study population consisted of all adult patients (age ≥ 18) who underwent their first 
auto-HCT following high dose melphalan (≥140 mg/m2) during the first year after diagnosis 
in the US or Canada and registered with CIBMTR between year 2007 and 2012. Patients 
who did not receive pre-transplant induction therapy with either thalidomide, lenalidomide 
or bortezomib, experienced disease progression prior to transplant, or in whom an allogeneic 
HCT was planned after auto-HCT were excluded. Due to limited numbers available for 
analysis, patients who received plerixafor for PBPC mobilization were also excluded.
Statistics
Patient-, disease- and transplant- related factors were compared between groups using the 
Chi-square test for categorical variables and the Wilcoxon two sample test for continuous 
variables. The probabilities of PFS and OS were calculated using the Kaplan-Meier 
estimator. Engraftment was compared using cumulative incidence estimates and considering 
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death from any cause as competing risk. Cox proportional hazards regression was used to 
compare the two mobilization strategies. The assumption of proportional hazards for each 
factor in the Cox model was tested by adding a time-dependent covariate. A stepwise model 
selection approach was used to identify all significant risk factors for each of the time-
dependent endpoints. Each step of model building contained the main effect for conditioning 
regimen types. The risk factors with significant level of p < 0.05 were included in the model. 
All computations were made with the statistical package SAS Version 9 (SAS Institute). All 
P values are 2-sided.
RESULTS
The analysis included 968 patients, 519 (from 62 centers) in GF and 449 (from 73 centers) 
in CC+GF. The median follow-up for survivors was 42 months in GF and 46 months in CC
+GF. Baseline characteristics are displayed in Table 1. The two cohorts had similar 
characteristics. There were more patients in GF with only one prior line of therapy, more 
prior use of lenalidomide in GF and thalidomide in CC+GF, more patients in complete 
remission and fewer patients with HCT comorbidity index (HCT-CI) of 0 in the GF cohort.
Mobilization and transplant outcomes
Patients completed product collection over a shorter time in CC+GF than in GF (P<0.001). 
The proportion of patients completing collection in 1, 2 and > 2 days was 33%, 29% and 
37% in GF vs. 52%, 21% and 26% in CC+GF respectively. Time from collection to 
transplant was slightly shorter in GF than in CC + GF (median 16 vs. 18 days, P<0.001). 
Characteristics of the product infused were available for 242 patients in GF (47%) and 147 
patients in CC + GF (33%). Fewer CD34+ cells were infused in patients mobilized with GF 
(median 3.9 × 106/kg, interquartile range 3.1–4.8 × 106/kg) than in CC + GF (median 5.1 × 
106/kg, interquartile range 3.5–6.9 × 106/kg, P < 0.001).
Neutrophil engraftment (≥ 0.5 × 109/L) was similar between groups (median 13 vs. 13 days, 
P=0.69) while platelet engraftment (≥ 20 × 109/L) was faster in CC+GF (median 19 vs. 18 
days, P=0.006, Figure 1). Number of inpatient days during first 100 days after transplant, a 
surrogate of short term morbidity, did not differ between the two groups (median 14 days, 
P=0.70). NRM at 1 year also was not affected by mobilization strategy (2% in GF vs. 1% if 
CC+GF, P=0.42)
Disease control and survival outcomes
In the univariate analysis, PFS at 1 year, 3 years and 5 years from auto-HCT were 77%, 
43%, 19% in GF and 79%, 40%, 26% in CC+GF respectively (P=0.76). The OS at 1 year, 3 
years and 5 years from auto-HCT were 95%, 82% and 63% for GF and 92%, 80% and 60% 
for CC+GF respectively (P=0.20).
In the multivariate analysis, Karnofsky score at transplant and stage at diagnosis affected 
PFS. Neither MM isotype, number of prior regimens of therapy, response to therapy prior to 
auto-HCT, use of planned second auto-HCT or HCT-CI contributed to the final PFS model 
(Table 2). Mobilization strategy was also not predictive of PFS (P=0.93, Figure 2 and Table 
3). The factors associated with OS were MM isotype, stage at diagnosis and HCT-CI. 
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Mobilization strategy was not associated with OS (P=0.27, Figure 2 and Table 3). There 
were 107 deaths in GF and 116 in CC+GF. MM was the main cause of death in both GF and 
CC+GF (79% and 78% respectively). Second malignancies (4% vs. 2%), infection (3% vs. 
3%) and organ failure (3% vs. 6%) accounted for similar proportions of deaths in both 
cohorts.
Many individual centers reported patients who were mobilized using both strategies raising 
the possibility of selection bias (Supplementary Table 1), i.e. centers could have assigned 
patients with more aggressive or refractory disease to CC+GF. To address this concern we 
compared PFS and OS between the two cohorts restricting analysis to centers that reported 
>70% of patients in one or the other mobilization strategy. Additionally we compared 
patients receiving CC+GF as the non-preferred strategy (i.e. CC+GF from centers that had 
>70% GF based mobilization) versus those receiving it as the preferred center strategy. 
These analyses did not indicate any difference between cohorts in PFS (Supplemental Table 
1 and supplemental figures)
DISCUSSION
In this report, we compare the outcomes of patients with MM undergoing auto-HCT 
following high dose melphalan according to mobilization strategy. Previous studies of 
mobilization strategy primarily examined the impact on CD34+ yields and engraftment 
kinetics and were comprised of patients who received alkylator based induction therapy. In 
contrast, this study was limited to indivduals who received immunomodulatory agents 
(IMiDs) or proteasome inhibitors during induction therapy. Our results are consistent with 
previous reports in which mobilization with the combination of chemotherapy and G-CSF 
was associated with fewer collection days and more CD34+ cells infused than G-CSF 
alone.5,13 Neutrophil and platelet engraftment were comparable between the two 
groups.16, 17,19
In addition, previous studies were primarily single center studies with limited follow up and 
were not designed to analyze the impact of mobilization strategy on long term disease 
control. In the multivariate analysis presented here, we did not detect any differences in PFS 
or OS based on mobilization strategy. 5, 18, 19 A more recent, single-center retrospective 
analysis also showed no benefit of chemotherapy mobilization on long term outcomes.20
The treatment landscape for MM has changed dramatically over the past decade with the 
introduction of the immunomodulatory agents (IMiDs) and the proteasome inhibitors. 
Incorporation of these less toxic and highly effective agents into two and three drug 
induction regimens has resulted in an increased rate and depth of response prior to transplant 
with improved OS.21 Furthermore, the increasing use of maintenance therapy has improved 
PFS and possibly OS post-transplant.22, 23 For this reason, the need for additional 
cytoreduction with cytotoxic chemotherapeutic agents such as cyclophosphamide in the 
mobilization regimen may no longer be necessary or relevant for disease control in 
myeloma.
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The other potential benefit of CC+GF mobilization is increased CD34 yields compared to 
GF alone. However, others have observed that the mobilization failure rates did not differ 
substantially between GF and CC+GF.17 In addition, the development of the CXCR4 
antagonist, plerixafor, can improve the CD34 yields and decrease rates of mobilization 
failures without using cytotoxic chemotherapy.24
Our study has some important limitations. Because of a limited sample size and markedly 
different patient characteristics, we were unable to analyze patients who received plerixafor 
in this study. Patients included in the present study received auto-HCT before or shortly after 
approval of plerixafor by the U.S. Food and Drug Administration and much of the early 
adoption of plerixafor may have been for patients who had already failed another 
mobilization modality or who were perceived to be at risk of failure, further impairing a fair 
comparison with GF and CC+GF. We believe, however, that the present work is still relevant 
in a scenario where plerixafor is an established option for upfront mobilization as the 
combination of plerixafor + GF is not expected to have an effect on disease control 
dissimilar to GF alone.
The CIBMTR database only collects data on the product infused at transplant (including 
data on mobilization) but not on products that are stored for later use, even if collected 
during the same mobilization cycle. Therefore we were unable to assess actual collection 
targets and yields and do not have any information on patients who were mobilized but not 
transplanted (“collect and store” or “mobilization failures”).
The other potential limitation of this study is that the decision to use CC + GF mobilization 
may be based on the presence of either high-risk disease or a high myeloma disease burden 
prior to auto-HCT. In our dataset, the two groups were very similar in both baseline 
characteristics which included both initial stage, number of prior lines of therapy, and 
response to induction therapy, factors that were all included in the multivariate analysis. In 
addition, an exploratory analysis of the dataset suggests that in the majority of cases, the 
method of mobilization is largely based on center preference rather than disease 
characteristics. Because of the nature of this database, comprehensive information on certain 
prognostic factors including fluorescent in situ hybridization, conventional cytogenetics or 
plasma cell labeling index was not available. We cannot exclude the possibility that a subset 
of patients with high disease burden or who are refractory to initial IMiD and proteasome 
inhibitor therapy may benefit from CC + GF mobilization since very few of these cases were 
available for analysis in the CIBMTR database (<5% of the population).
In summary, our data indicates that for patients with MM who received either an IMiD or 
bortezomib-based induction regimen, similar outcomes are observed post auto-HCT 
irrespective of the method of mobilization and found no evidence that the addition of 
chemotherapy to mobilization contributes to disease control.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Engraftment kinetics according to the method of mobilization.
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Figure 2. 
Adjusted probability of PFS and OS according to the method of mobilization
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Table 1
Characteristics of patients included in the study
Variable GF
(N=519)
CC+GF
(N=449)
P
Age at transplant 0.63
median (range) 58 (25–78) 58 (23–74)
18–39 15 (3%) 17 (4%)
40–49 80 (15%) 70 (16%)
50–59 218 (42%) 174 (39%)
60–69 182 (35%) 172 (38%)
≥70 24 (5%) 16 (4%)
Gender 0.78
Male 304 (59%) 259 (58%)
Female 215 (41%) 190 (42%)
Race 0.07
Caucasian 411 (79%) 335 (75%)
African American 89 (17%) 86 (19%)
Others, unknown 19 (4%) 28 (6%)
Karnofsky score 0.30
≥90 283 (55%) 261 (58%)
<90 193 (37%) 161 (36%)
Missing 43 (8%) 27 (6%)
HCT-Comorbidity Index 0.006
0 227 (44%) 227 (51%)
1–2 147 (29%) 134 (30%)
>2 145 (28%) 88 (20%)
Isotype 0.36
IgG 375 (72%) 333 (74%)
IgA 21 (4%) 19 (4%)
Light chain 101 (19%) 82 (18%)
Others, unknown 22 (5%) 15 (4%)
Stage III at diagnosis* 160 (31%) 162 (36%) 0.22
Number of prior therapy regimens** <0.001
1 382 (74%) 265 (59%)
2 113 (22%) 136 (30%)
>2 24 (5%) 48 (11%)
Prior therapy regimens** <0.001
Thalidomide + bortezomib +- corticosteroid 74 (14%) 92 (20%)
Lenalidomide+ bortezomib +- corticosteroid 121 (23%) 48 (11%)
Thalidomide +- corticosteroid 85 (16%) 106 (24%)
Bortezomib +- corticosteroid 132 (25%) 136 (30%)
Lenalidomide +- corticosteroid 107 (21%) 67 (15%)
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Variable GF
(N=519)
CC+GF
(N=449)
P
Sensitivity to initial therapy# 491 (95%) 426 (95%) 0.85
Overall cycles of chemotherapy
N evaluable 440 402
Median (range) 4 (1–42) 4 (1–20) 0.001
Prior radiation therapy 110 (21%) 101 (22%) 0.63
Response to initial therapy# 0.05
CR 84 (16%) 48 (11%)
PR/VGPR 407 (78%) 378 (84%)
MR/NR/SD 28 (5%) 23 (4%)
Mobilization cytotoxic chemotherapy
Cyclophosphamide 338 (75%)
Etoposide 55 (12%)
Cyclophosphamide + etoposide 21 (5%)
VDT-PACE/similar 35 (8%)
Year of transplant 0.03
2007–2008 289 (56%) 272 (61%)
2009–2010 105 (20%) 100 (22%)
2011–2012 125 (24%) 77 (17%)
Time from diagnosis to HCT <0.001
<6 months 221 (43%) 140 (31%)
6–12 months 298 (57%) 309 (69%)
Melphalan dose for conditioning therapy 0.40
140–180 mg/m2 71 (14%) 70 (16%)
>180 mg/m2 448 (86%) 379 (84%)
Number of transplants† 0.02
Single 417 (80%) 331 (74%)
Planned second auto-HCT 47 (9%) 69 (15%)
Salvage second transplant 55 (10%) 49 (11%)
Maintenance therapy 0.29
None 321 (62%) 273 (61%)
Thalidomide/lenalidomide +- corticosteroids 147 (28%) 134 (30%)
Thalidomide/lenalidomide + bortezomib +- corticosteroids 32 (6%) 30 (7%)
Bortezomib +- corticosteroids 16 (3%) 11 (2%)
Others 3 (<1%) 1 (<1%)
*
Durie-Salmon or International Staging System.
**
Excludes cytotoxic chemotherapy administered for mobilization.
#Assessed prior to mobilization.
†Analysis is for first transplant only
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Table 2
Multivariate analysis for progression-free survival and overall survival
Progression-free survival
Factor HR 95% C.I. P
Mobilization 0.93
GF 1.00
CC+GF 0.99 0.84–1.18
Karnofsky score, % 0.004
≥90 1.00
<90 1.21 1.01–1.45 0.04
Missing 1.61 1.18–2.20 0.003
Stage at diagnosis (ISS or DSS) 0.046
III 1.00
I or II 0.80 0.67–0.96 0.01
Unknown 0.93 0.64–1.36 0.71
Overall Survival
Factor HR 95% C.I. P
Mobilization 0.27
GF 1.00
CC+GF 1.16 0.89–1.52
Isotype 0.01
IgG/IgA/Others 1.00
Light chain/Non-secretory 0.62 0.43–0.88 0.009
Unknown 0.21 0.03–1.50 0.12
Stage at diagnosis (ISS or DSS) <0.001
III 1.00
I or II 0.54 0.41–0.71 <0.001
Unknown 0.51 0.26–0.97 0.04
HCT-CI 0.01
0–2 1.00
>2 1.48 1.09–2.03 0.01
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Table 3
Adjusted probabilities of outcomes
GF* CC+GF* P
Non relapse mortality
1–year 2 (1–4)% 1 (1–3)% 0.42
2–year 3 (1–4)% 2 (1–3)% 0.32
3–year 3 (1–4)% 2 (1–4)% 0.54
4–year 4 (2–6)% 3 (2–6)% 0.64
5–year 4 (2–6)% 3 (2–6)% 0.64
Progression-free survival
1–year 77 (73–81)% 79 (74–82)% 0.62
2–year 57 (52–61)% 62 (57–67)% 0.13
3–year 43 (38–48)% 40 (35–45)% 0.33
4–year 31 (26–37)% 31 (26–36)% 0.85
5–year 19 (13–25)% 26 (20–32)% 0.11
Overall survival
1–year 95 (92–96)% 92 (89–94)% 0.10
2–year 88 (84–90)% 85 (82–89)% 0.37
3–year 82 (78–86)% 80 (75–84)% 0.43
4–year 73 (68–78)% 71 (65–76)% 0.54
5–year 62 (54–68)% 60 (52–67)% 0.76
*
Percentage ( 95% confidence interval)
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